François Le Gal1, Sébastien Lebon2, Gian Paolo Ramelli3, Alexandre N Datta4, Danielle Mercati5, Oliver Maier6, Christophe Combescure7, Maria Isabel Rodriguez8, Margitta Seeck9, Eliane Roulet2, Christian M Korff10. 1. Psychiatric Genetic Unit, Genetic Medicine Service, University Hospitals, Geneva, Switzerland; Molecular Diagnostic Laboratory, Genetic Medicine Service, University Hospitals, Geneva, Switzerland. 2. Pediatric Neurology, CHUV, Lausanne, Switzerland. 3. Pediatric Neurology, Regional Hospital, Bellinzona, Switzerland. 4. Pediatric Neurology, Cantonal Hospital, Basel, Switzerland. 5. Pediatric Neurology, Cantonal Hospital, Neuchâtel, Switzerland. 6. Pediatric Neurology, Children's Hospital, St. Gallen, Switzerland. 7. Clinical Research Center, Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and University Hospitals, Geneva, Switzerland. 8. Clinical Research Platform, Child and Adolescent Department, University Hospitals, Geneva, Switzerland. 9. Clinical Neurosciences Department, University Hospitals, Geneva, Switzerland. 10. Pediatric Neurology, Child and Adolescent Department, University Hospitals, Geneva, Switzerland. Electronic address: christian.korff@hcuge.ch.
Abstract
PURPOSE: To identify clinical risk factors for Dravet syndrome (DS) in a population of children with status epilepticus (SE). MATERIAL AND METHODS: Children aged between 1 month and 16 years with at least one episode of SE were referred from 6 pediatric neurology centers in Switzerland. SE was defined as a clinical seizure lasting for more than 30min without recovery of normal consciousness. The diagnosis of DS was considered likely in previously healthy patients with seizures of multiple types starting before 1 year and developmental delay on follow-up. The presence of a SCN1A mutation was considered confirmatory for the diagnosis. Data such as gender, age at SE, SE clinical presentation and recurrence, additional seizure types and epilepsy diagnosis were collected. SCN1A analyses were performed in all patients, initially with High Resolution Melting Curve Analysis (HRMCA) and then by direct sequencing on selected samples with an abnormal HRMCA. Clinical and genetic findings were compared between children with DS and those with another diagnosis, and statistical methods were applied for significance analysis. RESULTS: 71 children with SE were included. Ten children had DS, and 61 had another diagnosis. SCN1A mutations were found in 12 of the 71 patients (16.9%; ten with DS, and two with seizures in a Generalized Epilepsy with Febrile Seizures+(GEFS+) context). The median age at first SE was 8 months in patients with DS, and 41 months in those with another epilepsy syndrome (p<0.001). Nine of the 10 DS patients had their initial SE before 18 months. Among the 26 patients aged 18 months or less at initial SE, the risk of DS was significantly increased for patients with two or more episodes (56.3%), as compared with those who had only one episode (0.0%) (p=0.005). CONCLUSION: In a population of children with SE, patients most likely to have DS are those who present their initial SE episode before 18 months, and who present with recurrent SE episodes.
PURPOSE: To identify clinical risk factors for Dravet syndrome (DS) in a population of children with status epilepticus (SE). MATERIAL AND METHODS:Children aged between 1 month and 16 years with at least one episode of SE were referred from 6 pediatric neurology centers in Switzerland. SE was defined as a clinical seizure lasting for more than 30min without recovery of normal consciousness. The diagnosis of DS was considered likely in previously healthy patients with seizures of multiple types starting before 1 year and developmental delay on follow-up. The presence of a SCN1A mutation was considered confirmatory for the diagnosis. Data such as gender, age at SE, SE clinical presentation and recurrence, additional seizure types and epilepsy diagnosis were collected. SCN1A analyses were performed in all patients, initially with High Resolution Melting Curve Analysis (HRMCA) and then by direct sequencing on selected samples with an abnormal HRMCA. Clinical and genetic findings were compared between children with DS and those with another diagnosis, and statistical methods were applied for significance analysis. RESULTS: 71 children with SE were included. Ten children had DS, and 61 had another diagnosis. SCN1A mutations were found in 12 of the 71 patients (16.9%; ten with DS, and two with seizures in a Generalized Epilepsy with Febrile Seizures+(GEFS+) context). The median age at first SE was 8 months in patients with DS, and 41 months in those with another epilepsy syndrome (p<0.001). Nine of the 10 DS patients had their initial SE before 18 months. Among the 26 patients aged 18 months or less at initial SE, the risk of DS was significantly increased for patients with two or more episodes (56.3%), as compared with those who had only one episode (0.0%) (p=0.005). CONCLUSION: In a population of children with SE, patients most likely to have DS are those who present their initial SE episode before 18 months, and who present with recurrent SE episodes.